Prof. Laura Van ‘T Veer, Ph.D., Cheif Research Officer (CRO) and Co-Founder of Agendia and UCSF Helen Diller Family Cancer Center @UCSFMedicine discusses MINDACT: Long-term results of the large prospective trial testing the 70-gene signature MammaPrint as guidance for adjuvant chemotherapy in breast cancer patients presented at this year’s virtual ASCO.
Laura J van ‘t Veer, Ph.D. on Availability on MINDACT in Breast Cancer #ASCO2020 @UCSFMedicine
